Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

HDM1002

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

Huadong Medicine · Phase 1 · Status n/r · Enrollment 30

NCT06601517

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatinn/rn/rn/rn/r

Not shown

  • HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatin: endpoint not reported